Ibuprofen & Budesonide Interaction

Ibuprofen (an NSAID) and budesonide (a corticosteroid) combined significantly increase the risk of gastrointestinal bleeding, peptic ulceration, and GI perforation. This is a clinically important major drug interaction, especially relevant for patients taking oral budesonide (e.g., for Crohn disease or eosinophilic esophagitis) alongside over-the-counter NSAIDs. Both agents impair GI mucosal defense through complementary mechanisms.

Ibuprofen inhibits COX-1 and COX-2, reducing protective prostaglandin synthesis in the gastric mucosa. Budesonide, acting systemically (even when formulated as enteric-release), inhibits phospholipase A2 through glucocorticoid receptor-mediated mechanisms, reducing arachidonic acid availability for prostaglandin production. Additionally, budesonide reduces mucus production and impairs mucosal repair. The combination eliminates multiple layers of mucosal protection, creating additive GI injury risk.

Data from multiple epidemiological studies confirm the multiplicative risk of GI events when corticosteroids and NSAIDs are co-administered. Although budesonide has lower systemic bioavailability than prednisone (approximately 10–15%), systemic exposure is not negligible and accumulates with dose and duration. The GI risk is particularly relevant in the Crohn disease population, who already have mucosal vulnerability, and in elderly patients.

Avoid concurrent systemic ibuprofen in patients on oral budesonide. For pain or fever management, substitute acetaminophen (up to 3g/day in most adults) as a safer alternative. If NSAID therapy is unavoidable, prescribe a proton pump inhibitor (e.g., omeprazole 20–40 mg daily) and use the lowest effective dose for the shortest duration. Counsel patients that OTC ibuprofen/NSAIDs should not be taken without provider guidance while on budesonide.

Stool color (melena) and GI bleeding symptoms. Hemoglobin if GI bleeding is suspected. Blood pressure and renal function (NSAID-related). Blood glucose (corticosteroid-related hyperglycemia). GI symptom assessment at each visit.

Acetaminophen is the preferred analgesic/antipyretic alternative. Topical NSAIDs (e.g., diclofenac gel) may be used for localized musculoskeletal pain with minimal systemic exposure. Celecoxib with a PPI has a reduced GI bleeding risk compared to non-selective NSAIDs if an anti-inflammatory effect is specifically needed.